Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New Application of TAP’s Automated Cell Culture System at AACR

Published: Saturday, April 05, 2014
Last Updated: Saturday, April 05, 2014
Bookmark and Share
Offers rapid production and consistent quality of NCI 60 cancer cell line panel.

TAP Biosystems has announced a new NCI 60 application for its CompacT SelecT™, a system that automates cell culture and processing in T-flasks and microplates. The details of the application, which will deliver a full NCI 60 panel within a working week, are available on Booth 1846 at the AACR.

On the booth, TAP Biosystems’ experts will explain how using an intelligently designed, simple, five-day workflow it is possible to maintain cancer cell line panels, such as the NCI 60, on a CompacT SelecT and also generate assay plates for each cell line during a working week, thus saving thousands of hours of manual cell culture processing tasks.

Pivotal to this workflow are the CompacT SelecT’s integrated cell counter and confluence measurement capabilities. The cell counter ensures seeding density is consistent and regularly scheduled confluence measurements reliably predict when cell lines will reach their ideal harvest conditions.

This allows each flask, irrespective of cell line, to be processed so that flasks are harvested at optimal confluence. Depending on seeding density required for assay plates, harvesting a single T-175 flask could produce sufficient cells for five to ten 96-well plates, as well sufficient cells for seeding new daughter flasks to maintain the cell line.

By linking sequences of work including expansion, media exchanges and plating the system can be set up and run to ensure production of consistent NCI 60 cell line panels, without the need for error prone manual cell culture. This allows researchers constant access to high quality assay-ready cells for research, screening or profiling activities.

Dr Dave Thomas, Product Manager at TAP Biosystems explained: “Maintaining the NCI 60 cell line panel is a very time consuming task. However, because it can be cultured in a common basal media, the reagent requirements are minimal and as doubling times for the majority of the cell lines allow the majority to be passaged on either a three or four day schedule this enabled us to devise a simple five day workflow for culturing and maintaining the entire panel on a single CompacT SelecT.”

Thomas added: “We’re look forward to meeting scientists on Booth 1846 and discussing how this application of the CompacT SelecT could significantly reduce cell culture time and resource demands for researchers, as well as improve the consistency of cells they use in their oncology programmes.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

TAP Biosystems Presents New Data on 3D Cell Culture Research
Discussing the application of RAFT 3D models in oncology, toxicology and neuroscience cell-based screening programmes.
Monday, January 20, 2014
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
Supercomputing and Drug Discovery
New biotech company uses supercomputer simulations to speed up drug discovery and biotech molecule development.
Preventing Breast Cancer with Hops
Study of hops extract suggests prevention of breast cancer through chemical pathway activation.
Treatment Advancement for Gaucher and Parkinson's Diseases
NIH scientists identify molecule that may act as a possible treatment of neurological diseases.
Biomunex Confirms Optimal Properties and Activity of BiXAb® Antibodies
Biomunex‘s Plug-and-Play bispecific antibodies demonstrated excellent in vitro properties and in vivo activity positively differentiating their BiXAb platform from competing formats.
Liquid Biopsy Predicts Colon Cancer Recurrence
Scientists have used a genetic test that spots bits of cancer-related DNA circulating in the blood to accurately predict the likelihood of the disease’s return in some — but not all — of a small group of patients with early-stage colon cancer.
New Treatment for Rare Blood Cancers
Drug called midostaurin showed promise in an international clinical trial led by a Stanford physician.
Biomarker for Parkinson's Disease Found in Urine Samples
Protein identified as Parkinson's biomarker sourced from patient's stored frozen urine samples.
Testing for Malaria or Cancer at Home
Chemist develops tech to save lives in rural Africa.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!